Generic, Brand ProAmatine Gap Could Leave Opening for Chelsea

A planned withdrawal at the end of the month of generic and brand versions of the low blood pressure drug ProAmatine will likely boost the fortunes of Chelsea Therapeutics’ lead candidate. If approved, Chelsea’s Northera (droxidopa), now in Phase III for the treatment of neurogenic orthostatic hypotension, would become the only FDA-approved drug for the condition upon ProAmatine’s (midodrine HCl) departure from the market. Chelsea is planning an NDA filing in the first half of next year.
Generic Line